If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksInt Diag Hld Regulatory News (IDHC)

Share Price Information for Int Diag Hld (IDHC)

Share Price is delayed by 15 minutes
Get Live Data
0.504    0.002 (0.40%)
Bid:
0.504
Ask:
0.51
Spread: 0.006 (1.19%)
Market Cap: $292.99m
IDHC Live PriceLast checked at - London Stock Exchange

Intraday Int Diag Hld Share Chart

Form 8 - Integrated Diagnostics Holdings Plc

Today 12:47

RNS Number : 0185L
Integrated Diagnostics Holdings PLC
03 July 2026
Β 

FORM 8 (OPD)

Β 

PUBLIC OPENING POSITION DISCLOSURE BY A PARTY TO AN OFFER

Rules 8.1 and 8.2 of the Takeover Code (the "Code")

Β 

1. KEY INFORMATION

Β 

(a) Full name of discloser:

Integrated Diagnostics Holdings plc

(b) Owner or controller of interests and short positions disclosed, if different from 1(a):

The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.

(c) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

Integrated Diagnostics Holdings plc

(d) Is the discloser the offeror or the offeree?

OFFEREE

(e) Date position held:

The latest practicable date prior to the disclosure

26 June 2026

(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?

If it is a cash offer or possible cash offer, state "N/A"

N/A

Β 

Β 

2. POSITIONS OF THE PARTY TO THE OFFER MAKING THE DISCLOSURE

Β 

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

Β 

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates

Β 

Class of relevant security:

Β 

Ordinary Shares of USD0.25 each

("Ordinary Shares")

Β 

Β 

Interests

Short positions

Number

%

Number

%

(1) Relevant securities owned and/or controlled:

Nil

Nil

Nil

Nil

(2) Cash-settled derivatives:

Β 

Nil

Nil

Nil

Nil

(3) Stock-settled derivatives (including options) and agreements to purchase/sell:

Nil

Nil

Nil

Nil

Β 

TOTAL:

Nil

Nil

Nil

Nil

Β 

All interests and all short positions should be disclosed.

Β 

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental FormΒ 8 (Open Positions).

Β 

Details of any securities borrowing and lending positions or financial collateral arrangements should be disclosed on a Supplemental Form 8 (SBL).

Β 

(b) Rights to subscribe for new securities

Β 

Class of relevant security in relation to which subscription right exists:

N/A

Details, including nature of the rights concerned and relevant percentages:

N/A

Β 

Β 

3. POSITIONS OF PERSONS ACTING IN CONCERT WITH THE PARTY TO THE OFFER MAKING THE DISCLOSURE

Β 

Details of any interests, short positions and rights to subscribe (including directors' and other employee options) of any person acting in concert with the party to the offer making the disclosure:

Β 

a) Interests comprising Ordinary Shares held by the independent directors of Integrated Diagnostics Holdings plc, their close relatives and related trusts:

Β 

Director

Number of Ordinary Shares held

Percentage of total issued ordinary share capital

Anthony St John

50,000

0.01%

Yvonne Stillhart

230,000

0.03%

Total:

280,000

0.04%

Β 

Β 

Β 

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

Β 

Details of any securities borrowing and lending positions or financial collateral arrangements should be disclosed on a Supplemental Form 8 (SBL).

Β 

4. OTHER INFORMATION

Β 

(a) Indemnity and other dealing arrangements

Β 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the party to the offer making the disclosure or any person acting in concert with it:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"

Β 

None

Β 

Β 

(b) Agreements, arrangements or understandings relating to options or derivatives

Β 

Details of any agreement, arrangement or understanding, formal or informal, between the party to the offer making the disclosure, or any person acting in concert with it, and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

Β 

None

Β 

Β 

(c) Attachments

Β 

Are any Supplemental Forms attached?

Β 

Supplemental Form 8 (Open Positions)

NO

Supplemental Form 8 (SBL)

NO

Β 

Β 

Date of disclosure:

3 July 2026

Contact name:

Charles Wood

Telephone number:

+44 (0)204 617 1053

Β 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

Β 

The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.

Β 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

Β 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Β 
END
Β 
Β 
FEEFLFSLDSIVIIR
Date   Source Headline
3rd Jul 202612:47 pmRNSForm 8 - Integrated Diagnostics Holdings Plc
3rd Jul 20267:00 amRNSForm 8.3 - Integrated Diagnostics Holdings PLC
2nd Jul 20263:25 pmRNSForm 8.3 - INTEGRATED DIAGNOSTICS HOLDINGS PLC
1st Jul 20264:44 pmRNSForm 8.3 - Integrated Diagnostics Holdings PLC
1st Jul 20263:17 pmRNSForm 8.3 - INTEGRATED DIAGNOSTICS HOLDINGS PLC
1st Jul 202610:56 amRNSOPD Rule 8.3 – Integrated Diagnostics Holdings plc
1st Jul 20267:00 amRNSForm 8.3 - Integrated Diagnostics Holdings Replace
1st Jul 20267:00 amRNSForm 8.3 - Integrated Diagnostics Holdings Replace
30th Jun 20264:20 pmRNSForm 8.3 - Integrated Diagnostics Holdings PLC
30th Jun 20267:00 amRNSForm 8.3 - Integrated Diagnostics Holdings PLC
29th Jun 202610:12 amRNSForm 8.3 - Integrated Diagnostics Holdings PLC
26th Jun 20265:06 pmRNSForm 8.3 - Integrated Diagnostics Holdings PLC
26th Jun 20265:04 pmRNSForm 8.3 - Integrated Diagnostics Holdings PLC
26th Jun 20264:59 pmRNSForm 8.3 - Integrated Diagnostics Holdings PLC
25th Jun 20262:47 pmRNSForm 8.3 Integrated Diagnostics Holdings Plc
25th Jun 20267:00 amPRNForm 8.3 - Integrated Diagnostics Holdings plc
24th Jun 20263:37 pmRNSHolding(s) in Company
24th Jun 20263:19 pmRNSForm 8.3 - INTEGRATED DIAGNOSTICS HOLDINGS PLC
24th Jun 20262:30 pmRNSForm 8 (OPD) - IDH plc - Hena Holdings Ltd
24th Jun 202610:44 amRNSForm 8.3 - Integrated Diagnostic Holdings plc
24th Jun 20269:26 amPRNForm 8.3 - Integrated Diagnostics Holdings plc
23rd Jun 20265:05 pmRNSDirector/PDMR Shareholding
23rd Jun 20265:03 pmRNSHolding(s) in Company
23rd Jun 20263:53 pmRNSStatement re Mandatory Final Cash Offer
23rd Jun 202610:41 amRNSDisclosure Table
23rd Jun 202610:15 amRNSMANDATORY FINAL CASH OFFER
20th May 20262:05 pmRNSReplacement - 1st Quarter Results
20th May 20267:00 amRNS1st Quarter Results
19th May 20265:09 pmRNSResult of AGM
30th Apr 202612:39 pmRNSReplacement - Holding(s) in Company
23rd Apr 20261:06 pmRNSAnnual Financial Report & Notice of AGM
17th Apr 20267:00 amRNSFinal Results
8th Apr 20265:50 pmRNSHolding(s) in Company
8th Apr 20265:49 pmRNSHolding(s) in Company
13th Nov 20257:00 amRNS3rd Quarter Results
7th Nov 20257:00 amRNSNotice of Results
2nd Sep 20257:00 amRNSHalf-year Report
29th Aug 202511:55 amRNSNotice of Results
20th Jun 20257:00 amRNSIDH Strengthens Egyptian Radiology portfolio
28th May 20257:00 amRNS1st Quarter Results
27th May 20255:00 pmRNSResult of AGM
22nd May 20257:00 amRNSNotice of Results
24th Apr 20253:30 pmRNSAnnual Financial Report & Notice of AGM
17th Apr 20257:00 amRNSFinal Results
10th Apr 20254:41 pmRNSNotice of Results
9th Dec 202410:59 amRNSIDH INCREASES STAKE IN BIOLAB KSA
14th Nov 20247:00 amRNS3rd Quarter Results
11th Nov 202411:29 amRNSNotice of Results
8th Oct 20245:21 pmRNSCancellation of Treasury Shares
1st Oct 20249:00 amRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.